OTCMKTS:CNBX CNBX Pharmaceuticals (CNBX) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CNBX Stock Alerts $0.01 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.0107▼$0.012550-Day Range$0.0104▼$0.017052-Week Range$0.01▼$0.05Volume1.21 million shsAverage Volume254,335 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get CNBX Pharmaceuticals alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About CNBX Pharmaceuticals Stock (OTCMKTS:CNBX)CNBX Pharmaceuticals Inc., a clinical stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. The company is a subsidiary of Cannabics Inc.Read More CNBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNBX Stock News HeadlinesNovember 24, 2023 | benzinga.comCNBX Pharmaceuticals Stock (OTC:CNBX) Dividends: History, Yield and DatesNovember 5, 2023 | morningstar.comCNBX Pharmaceuticals Inc CNBXApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 10, 2023 | investing.comCNBX Historical DataJuly 28, 2023 | finance.yahoo.comCNBX - CNBX Pharmaceuticals Inc.November 8, 2022 | benzinga.comCNBX Acquires A Controlling Interest In Cancer Immunotherapy DeveloperNovember 8, 2022 | finance.yahoo.comCNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza BiopharmaOctober 18, 2022 | finance.yahoo.comCNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer TherapyApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 13, 2022 | finance.yahoo.comCNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and IsraelSeptember 28, 2022 | finance.yahoo.comCNBX Pharmaceuticals Announces New Patent Granted in AustraliaSeptember 12, 2022 | reuters.comCNBX Pharmaceuticals IncAugust 16, 2022 | ca.finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBX)June 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Earnings Estimates, EPS, and RevenueJune 10, 2022 | benzinga.comCNBX Pharmaceuticals (OTC:CNBXD), Analyst Ratings, Price Targets, PredictionsJune 7, 2022 | finance.yahoo.comCNBX Pharmaceuticals Inc. (CNBXD)May 31, 2022 | finance.yahoo.comCNBX Pharmaceuticals Release a New Corporate PresentationMay 14, 2022 | barrons.comCNBX Pharmaceuticals Inc.May 5, 2022 | seekingalpha.comCNBX pharma granted patent in Hong Kong for cancer therapyMay 5, 2022 | finance.yahoo.comCNBX Pharmaceuticals Granted Patent in Hong KongApril 4, 2022 | msn.comNovartis to save at least $1 billion by 2024 thanks to simplified structureApril 4, 2022 | msn.comVertex Pharma sees positive results in Phase 2 trials of new non-opioid pain killerApril 4, 2022 | cnbc.comWhat to watch today: Wall Street looks higher; Twitter soars on Elon Musk stakeApril 4, 2022 | msn.comStocks making the biggest moves in the premarket: Twitter, Tesla, Starbucks and moreApril 1, 2022 | cnbc.comCNBC Transcript: Johnson & Johnson CEO Joaquin Duato Speaks with CNBC’s Meg Tirrell Live During CNBC’s Healthy Returns Summit TodayApril 1, 2022 | cnbc.comWhat to watch today: Wall Street set to wrap up strong month but weak quarterApril 1, 2022 | msn.comStocks making the biggest moves premarket: Walgreens, Baidu, Novavax and othersSee More Headlines Receive CNBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNBX Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryCannabis Current SymbolOTCMKTS:CNBX CUSIPN/A CIK1343009 Webwww.cannabics.com Phone(877) 424-2429FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Gabriel Yariv (Age 48)President, COO & Executive Chairman Comp: $241.67kMr. Uri Ben-Or CPA (Age 54)CPA, M.B.A., MBA, Chief Financial Officer Comp: $40.32kMr. Eyal Barad (Age 59)Co-Founder, CEO & Director Comp: $269.15kDr. Sanja Goldberg (Age 48)Chief Technology Officer Comp: $48.12kNoam PermontVice President of Public Relations & Investor RelationsDr. Sigalit Ariely-Portnoy Ph.D. (Age 60)Senior Advisor of Regulation, Validation & Quality and Member of Advisory Board Dr. Tal Mofkadi Ph.D.Financial Advisor & Member of Advisory BoardMr. Yasha Borstein (Age 61)Chief Data Officer Dr. Yaakov Waksman (Age 72)Head of Cannabidiol Research Dr. Ilya Reznik M.D.Head of Neuropsychiatry DevelopmentMore ExecutivesKey CompetitorsGB SciencesOTCMKTS:GBLX180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All Competitors CNBX Stock Analysis - Frequently Asked Questions How have CNBX shares performed in 2024? CNBX Pharmaceuticals' stock was trading at $0.0142 on January 1st, 2024. Since then, CNBX shares have decreased by 23.9% and is now trading at $0.0108. View the best growth stocks for 2024 here. Are investors shorting CNBX Pharmaceuticals? CNBX Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 300 shares, an increase of 200.0% from the March 15th total of 100 shares. Based on an average daily volume of 56,600 shares, the days-to-cover ratio is presently 0.0 days. View CNBX Pharmaceuticals' Short Interest. When did CNBX Pharmaceuticals' stock split? CNBX Pharmaceuticals's stock reverse split before market open on Thursday, May 12th 2022. The 1-120 reverse split was announced on Thursday, May 12th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of CNBX Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNBX Pharmaceuticals investors own include Gran Tierra Energy (GTE), Organigram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA). How do I buy shares of CNBX Pharmaceuticals? Shares of CNBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CNBX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressThe World's First "$20 Trillion Drug?"Behind the MarketsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNBX Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
